
    
      Recombinant humanized anti-PD-1 monoclonal antibody combined with albumin paclitaxel and
      bevacizumab treatment, once every 3 weeks, treatment until disease progression, intolerable
      adverse reactions, patient death or withdrawal informed agree.After treatment, the patients
      was followed up every 9 weeks for follow-up treatment and survival.
    
  